Dutch AI Startup Wins €1M Prize with Healthcare Innovation at Slush 2024
Helsinki, Friday, 22 November 2024.
OASYS NOW, founded by Nima Salami after his refugee mother’s healthcare struggles, revolutionizes clinical trial recruitment with AI. Their platform reduces patient identification time from months to minutes, addressing an industry where 80% of trials fail to meet enrollment targets. The €1M investment will accelerate their expansion into brain diseases and immunology while maintaining strict patient data privacy standards.
Revolutionizing Healthcare with AI
OASYS NOW’s groundbreaking platform leverages artificial intelligence to transform how clinical trials are conducted. The company, based in Delft, Netherlands, has developed a patient recruitment system that automates the identification of eligible participants by meta-crawling research trial criteria and cross-matching with electronic health records (EHRs). This technological innovation is crucial in an industry where a staggering 80% of clinical trials do not meet their initial enrollment targets, potentially costing drug developers millions in delays[1][2].
Impact of the Slush 100 Victory
Winning the Slush 100 competition not only brings a substantial €1 million equity investment from General Catalyst and Cherry Ventures but also provides OASYS NOW with mentorship from industry leaders. This victory is expected to significantly bolster the company’s capabilities, allowing them to expand their team and enhance the computing power of their services. Moreover, the investment will support their strategic expansion into high-need areas such as brain diseases, including Alzheimer’s and Parkinson’s, as well as immunology[1][3].
Empowering Patients and Ensuring Privacy
Central to OASYS NOW’s mission is empowering patients through their GRIP app and ELaiGIBLE platform, which give users control over their health data and facilitate the discovery of relevant clinical trials. The company places a strong emphasis on data privacy, ensuring compliance with General Data Protection Regulation (GDPR) standards and using encrypted, anonymized data. This patient-centric approach not only enhances trust but also positions OASYS NOW as a leader in ethical healthcare innovation[1][3].
A Vision for the Future of Clinical Research
Looking ahead, OASYS NOW aims to continue at the forefront of digital healthcare innovation by adapting their technology to various therapeutic areas. The adaptability of their platform allows for seamless integration into different healthcare environments, thereby addressing a broad spectrum of clinical challenges. With the recent investment and increased visibility from their Slush 100 victory, OASYS NOW is poised to make personalized medicine more accessible and effective, transforming the landscape of patient care globally[1][3].